Beyond the hype: Where genomics is having an impact on outcomes

IE users – if you are experiencing issues trying to register for this webinar, please use Chrome, Safari or Firefox.

Tues., Nov. 27, 2018
1:00 PM ET / 10:00 AM PT

Precision medicine has begun to deliver important answers for patients who have diseases with a genetic component—cancer and some neurological diseases, in particular. But understanding how next-generation sequencing and emerging technologies can be applied to diagnosing, preventing, and treating certain conditions can be challenging without evidence of their effectiveness. Health plans are often reluctant to commit to reimbursing what they consider unproven treatment plans, and many are still undecided about covering certain types of genetic testing.

Click here to register for this webinar where you’ll learn more about the rapid progress being made in linking genetic testing and personalized medicine to better health outcomes. From oncology to neurological disorders like Alzheimer’s disease, the speakers will discuss the diseases that are seeing the greatest potential and those areas that are still emerging.

 

Patrick James, MD

Chief Clinical Officer, Health Plans and Policy
Quest Diagnostics

 

 

 

 

Felicitas L. Lacbawan, MD, FCAP, FACMG

VP and Executive Medical Director of the Advanced Diagnostics
Quest Diagnostics

 

 

 

 

Bruce Quinn, MD, PhD

Principal

Bruce Quinn Associates LLC